Abstract
The aim of this ‘literature review’-based argumentative paper has been to find out the risks of developing psychotic and depressive disorders in patients having been treated with antidepressants. In order to reach a resounding supposition, this literature review-based argumentative study had taken an incisive look into previous research works and meta-analysis, which in effect had underscored the risks of antidepressant-induced psychotic and depressive disorders in patients with depression as well as psychosis even as the protagonists of antidepressant drug classes could not be undermined given their upscaled magnitude of benefits. While following a probing interpretation of past studies, this might be demystified that antidepressants could lead to psychotic events and depressive disorders in patients of all age groups with children and young adults being more susceptible to develop psychosis. The psychotic episodes could even be developed during initial phase of treatments in patients suffering from depressive and psychotic disorders such as bipolar mood disorder, unipolar depression, major depressive disorders, mania, OCD (Obsessive Compulsive Disorder), delusional depression (psychotic depression), schizophrenia, schizoaffective disorders alongside multiple somatic symptoms among others as well. Concomitantly, with efficaciousness of antidepressants in major depressive disorder still remaining a subject to utter dubitability, different antidepressant drug classes were found to be associated with a considerable scale of adverse effects after carrying out protracted arguments on findings of evidence-based past studies, meta-analysis of previous researches and relevant clinical cases. Therefore, following a systematized approach towards past studies, this argumentative research has reached a coherent conclusion that antidepressants are likely to cause psychotic events and exaggeration of depressive disorders up to some extent in several cases. Hence, there is a stipulation of individual risk-benefit assessment and intricate history taking in patients being contemplated for antidepressant drugs alongside a close observation and follow-up in patients of all age groups after introducing antidepressant medications.
Reference130 articles.
1. Alvano, S., Zieher, L., (2019). “An updated classification of antidepressants: A proposal to simplify treatment.” Personalized Medicine in Psychiatry. pp.19-20.
2. American Psychiatric Association (APA)., (2010). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. APA.
3. American Psychiatric Association (APA)., (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV). American Psychiatric Association, Washington, DC.
4. American Psychological Association (APA)., (2006). ‘Medicate or not. Monitor on Psychology.’
5. Amsterdam, J., D., (2006). “Monoamine oxidase inhibitor therapy in severe and resistant depression.” Psychiatr Ann. 36, pp.607-613.